 Updated results from Part A of the phase 2 MARCH study using both VIR-2218 and VIR3434 for Hepatitis B treatment are expected in the 2nd half of 2022. Results from the ongoing phase 2 study using VIR-2218 alone as a monotherapy and in combination with PEG-IFN-a for Hepatitis B are expected in the 2nd half of 2022. 